Targeting Colon Cancer Cells with Fluorescent Magnetic Nanoparticles Conjugated to Anti-epidermal Growth Factor Receptor Antibodies.
- Author:
Chang Wook KIM
1
;
Young Seok CHO
;
Tae Jong YOON
;
Hyung Keun KIM
;
Sung Soo KIM
;
Ki Yuk CHANG
;
Hiun Suk CHAE
;
Myung Gyu CHOI
;
Kyu Yong CHOI
Author Information
1. Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. yscho@catholic.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Colon cancer;
Fluorescent magnetic nanoparticle (FMNP);
EGFR
- MeSH:
Animals;
Antibodies;
Blotting, Western;
Cell Line;
Colon;
Colonic Neoplasms;
Ferric Compounds;
Fluorescence;
HT29 Cells;
Humans;
Iron;
Lung Neoplasms;
Magnetics;
Magnets;
Membranes;
Mice;
Microscopy, Confocal;
Nanoparticles;
Receptor, Epidermal Growth Factor;
Rhodamines;
Silicon Dioxide
- From:Korean Journal of Gastrointestinal Endoscopy
2008;36(1):1-6
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: The aim of this study was to evaluate targeting the epidermal growth factor receptors (EGFRs) of colon cancer cells with fluorescent magnetic nanoparticles (FMNP) conjugated to anti-EGFR antibodies. METHODS: The expression of EGFRs was evaluated in the HT-29 colon cancer cell lines and the control H-520 lung cancer cells by performing Western blot analysis. We synthesized silica-overcoated iron oxide nanoparticles that contained rhodamine B isothiocyanate (RITC) within a silica shell of a controllable thickness. This FMNP was conjugated to anti-EGFR mouse monoclonal antibody. The cells were treated with this probe conjugate for 4 hours and then the targeting was assessed via confocal microscopy. The fluorescence properties were evaluated for their binding to the expressed EGFRs with using a FACScan flow cytometer. RESULTS: EGFR was expressed in the HT-29 cells, as assessed by Western blot analysis. Red fluorescence was only detected in the membrane regions of the HT-29 cells on the confocal microscope imaging. On the FACS analysis, there was a significant shift of fluorescence intensity for the HT-29 cells. CONCLUSIONS: Our data show the feasibility of targeting colon cancer cells with FMNP conjugated with anti-EGFR antibodies in vitro.
